|

Daraxonrasib Clinical Trials

8 actively recruiting trials across 7 locations

▲ +1 trial since August 2026

Also known as: RMC 6236, RMC-6236

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 4Phase 1/2: 2

Top Sponsors

  • Revolution Medicines, Inc.7
  • Bristol-Myers Squibb1

Indications

Phoenix, Arizona2 trials

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Mayo Clinic

Phase 3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Mayo Clinic - Scottsdale

Phase 3

Birmingham, Alabama1 trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Alabama Oncology

Phase 3

Duarte, California1 trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

City of Hope

Phase 1/2

Los Angeles, California1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

San Francisco, California1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0096

Phase 2

New Haven, Connecticut1 trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Yale Cancer Center

Phase 1

Tampa, Florida1 trial

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Moffitt Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.